Valence-Logo
Beliebt
Anmelden
Loading data for OCSAW — first visit, this takes a few seconds.

Zur Watchlist hinzufügen

Oculis Holding AG

NasdaqGM: OCSAW · Echtzeitkurs · USD
5.02
-0.35 (-6.52%)
Zum Schluss: Aug 19, 2026, 11:12 AM

Kurs, die wichtigsten Kennzahlen und die neuesten Nachrichten an einem Ort.

Oculis Holding AG (OCSAW) Aktienkurs, Analyse & Daten

Geld1.85
Marktkapitalisierungn/a
Umsatz (TTM)n/a
Nettogewinn (TTM)n/a
n/a
n/a
n/a
n/a
KBV (TTM)1.15
KUV (TTM)n/a
Termin Quartalszahlenn/a
Briefn/a
Volumen0
Ø Vol. (20D)
Eröffnung9.91
Vortagesschlussn/a
Tagesspanne5.02 - 5.38
52-Wk Range5.02 - 5.38
Analystn/a
Kurszieln/a
Dividendenn/a
Ex-Dividenden-Datumn/a

Über OCSAW

A detailed description of the company is not yet available....

[Mehr lesen]
Branche n/a
Sektor n/a
IPO Datum Jul 17, 2026
Mitarbeiter n/a
Börse NasdaqGM
Tickersymbol OCSAW
Vollständiges Unternehmensprofil

Finanzielle Entwicklung

Im Jahr 2025 betrug der Umsatz von Oculis 0, ein Anstieg von undefined% im Vergleich zum Vorjahr (0). Der Gewinn lag bei -98.96 Mio, ein Anstieg von 15.37 %.

Finanzberichte
news image

vor 1 Woche · Zacks

Does Oculis Holding AG (OCS) Have the Potential to Rally 187.83% as Wall Street Analysts Expect?

The average of price targets set by Wall Street analysts indicates a potential upside of 187.8% in Oculis Holding AG (OCS). While the effectiveness of this highly sought-after metric is questionable, ...

news image

vor 1 Woche · MT Newswires

Oculis to Buy Accure's Global Development, Commercial Rights to Privosegtor

Oculis Holding (OCS) has agreed to acquire all of Accure Therapeutics' worldwide development and com

news image

vor 2 Wochen · Zacks

Oculis Holding AG (OCS) Reports Q2 Loss, Tops Revenue Estimates

Oculis Holding AG (OCS) delivered earnings and revenue surprises of +58.33% and +49.05%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

news image

vor 2 Monaten · Motley Fool

Nan Fung Group Sells $4.3 Million in Oculis Shares As Lead Drug Stumbles

Oculis advances late-stage topical therapies for diabetic and neuro-ophthalmic eye diseases in the clinical-stage biotech sector.

news image

vor 2 Monaten · Stocktwits

OCS Stock Drops Over 23% — Eye Drop Trial For Diabetic Vision Loss Misses Target

Oculis said it will not pursue US Food and Drug Administration (FDA) filing for OCS-01 in diabetic macular edema following disappointing late-stage trial results.

Seite 1 von 2